Telix Pharmaceuticals (TLX) Invested Capital (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Invested Capital for 3 consecutive years, with $405.0 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 45.63% to $405.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $744.9 million through Dec 2024, up 587.81% year-over-year, with the annual reading at $405.0 million for FY2025, 45.63% down from the prior year.
  • Invested Capital for Q4 2025 was $405.0 million at Telix Pharmaceuticals, down from $744.9 million in the prior quarter.
  • The five-year high for Invested Capital was $744.9 million in Q4 2024, with the low at $108.3 million in Q4 2023.
  • Average Invested Capital over 3 years is $419.4 million, with a median of $405.0 million recorded in 2025.
  • The sharpest move saw Invested Capital soared 587.81% in 2024, then tumbled 45.63% in 2025.
  • Over 3 years, Invested Capital stood at $108.3 million in 2023, then skyrocketed by 587.81% to $744.9 million in 2024, then crashed by 45.63% to $405.0 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $405.0 million, $744.9 million, and $108.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.